Cytori Cell Research Institute, Inc. (3750.T)
JPY 916.0
(-1.51%)
JPY 916.0
(-1.51%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | -1.15 Billion | -39.51 Million | -187.78 Million | -82.89 Million | 531 Million |
| Net Income | -1.01 Billion | -1.16 Billion | -65.33 Million | -654.24 Million | 319 Million |
| Depreciation & Amortization | 254.31 Million | 331.49 Million | 321.04 Million | 307.85 Million | 172 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | 211.5 Million | - |
| Change in working capital | 207.47 Million | 461.15 Million | -14.58 Million | 303.64 Million | 98 Million |
| Other non-cash items | 62.74 Million | 252.74 Million | -245.6 Million | -164.14 Million | -58 Million |
| Investing Cash Flow | 8.68 Billion | -283.06 Million | -216.19 Million | 6.7 Million | -7.42 Billion |
| Investments in PPE | -16.25 Million | -158.52 Million | -180.04 Million | -15.95 Million | - |
| Acquisitions | -1 Million | 198.49 Million | -212.21 Million | 15.61 Million | -1.6 Billion |
| Investment purchases | -150 Million | -322.86 Million | -205.51 Million | - | -169.06 Million |
| Sales/Maturities of investments | 600 Million | - | 282.81 Million | - | - |
| Other Investing Activities | -33.98 Million | -179 Thousand | 98.76 Million | 7.04 Million | -5.81 Billion |
| Financing Cash Flow | -7.17 Billion | 294.22 Million | 35.79 Million | 150.64 Million | 6.35 Billion |
| Debt repayment | -6.03 Billion | -239.15 Million | -288.81 Million | -220.8 Million | -5.73 Billion |
| Dividends payments | - | - | - | -67.11 Million | -134.25 Million |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | 258.65 Million | 61.18 Million | - |
| Other Financing Activities | -1.13 Billion | 55.06 Million | 65.95 Million | 377.38 Million | 753 Million |
| Accounts receivables | 192.25 Million | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | 15.21 Million | 88.65 Million | 211.93 Million | 303.64 Million | 246 Million |
| Other working capital | 52 Million | 624 Million | -471 Million | 47 Million | -148 Million |
| Cash at beginning of period | 673.05 Million | 701.55 Million | 1.06 Billion | 999.5 Million | 534 Million |
| Cash at end of period | 1.03 Billion | 673.05 Million | 701.55 Million | 1.06 Billion | -158 Thousand |
| Capital Expenditure | -16.25 Million | -158.52 Million | -180.04 Million | -15.95 Million | - |
| Effect of forex changes on cash | - | - | - | -4.21 Million | -158 Thousand |
| Net cash flow / Change in cash | 365.17 Million | -28.5 Million | -368.18 Million | 70.23 Million | -534.15 Million |
| Free Cash Flow | -1.16 Billion | -198.03 Million | -367.82 Million | -98.85 Million | 531 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -242 Million | 690 Million | -1.01 Billion | -109 Million | -282 Million | -161 Million |
| Depreciation & Amortization | - | - | 254.31 Million | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | 207.47 Million | - | - | - |
| Other non-cash items | 242 Million | -690 Million | 62.74 Million | 109 Million | 282 Million | 161 Million |
| Investing Cash Flow | - | - | 8.68 Billion | - | - | - |
| Investments in PPE | - | - | -16.25 Million | - | - | - |
| Acquisitions | - | - | -1 Million | - | - | - |
| Investment purchases | - | - | -150 Million | - | - | - |
| Sales/Maturities of investments | - | - | 600 Million | - | - | - |
| Other Investing Activities | - | - | -33.98 Million | - | - | - |
| Financing Cash Flow | - | - | -7.17 Billion | - | - | - |
| Debt repayment | - | - | -6.03 Billion | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | -1.13 Billion | - | - | - |
| Accounts receivables | - | - | 192.25 Million | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | 15.21 Million | - | - | - |
| Other working capital | - | - | 52 Million | - | - | - |
| Cash at beginning of period | - | - | 673.05 Million | - | - | - |
| Cash at end of period | - | - | 1.03 Billion | - | - | - |
| Capital Expenditure | - | - | -16.25 Million | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | 365.17 Million | - | - | - |
| Free Cash Flow | - | - | -1.16 Billion | - | - | - |
STRA
NSANY
688367
3883
ESSITY-B
2300